Globe Newswire
Frøya, 25 October 2026: Reference is made to the Company’s announcement of 1 October 2026 regarding the waiver agreement with its lenders. As 25 October 2026 falls on a non-banking day, the lenders have agreed to extend the waiver period until and including Monday, 26 October 2026. The Company remains in dialogue with its lenders and relevant stakeholders regarding its financing position and will provide a further update when appropriate.
For further information,... (continue reading...)
SUMPERK, Czech Republic, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Dormer Pramet has expanded its milling and threading portfolio with four product developments designed to help manufacturers increase productivity, improve process reliability and control cost per component. These additions support shoulder milling, chamfering, high-strength steel threading and high-feed roughing applications.
The launch includes the new STD11 and STD17 shoulder milling series, an expanded... (continue reading...)
TEL AVIV, Israel, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Sweet Security today disclosed new research findings expanding the known scope of the Node2Shell vulnerability beyond its original C implementation. Tomer Ben Gera, an engineer on Sweet Security’s sensor team, identified that a parallel fix was pushed to the Go implementation of the Brotli compression library on October 23, confirming the same vulnerability class existed in Go.
The finding significantly expands the... (continue reading...)
Remittix opens applications for 100 Earn testers with ETH, USDT and USDC deposits, targeted yields of 18–22% APY and deposit-matched RTX token gifts.
MAJURO, Marshall Islands, Oct. 25, 2026 (GLOBE NEWSWIRE) -- Remittix is preparing weekly payouts through an initial test of its Earn platform, giving selected participants access to targeted yields of 18–22% APY on ETH, USDT and USDC. The programme will accommodate 100 testers, with a minimum deposit equivalent to... (continue reading...)
MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October... (continue reading...)
More Globe Newswire
View Older Stories-
Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer
-
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
-
Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform
-
Crypto News: Remittix Announces 300 Million RTX Burn at Launch as JPMorgan Brings Two Tokenized Funds to Solana, Building the Case for a $300 SOL Price Prediction
-
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
-
Amarin Provides Update on University of Leeds Sponsored Phase 3 EPA for Metastasis Trial 2 (EMT2) Evaluating VAZKEPA®/VASCEPA® (icosapent ethyl) Capsules on Top of Standard of Care Treatment in Pati
-
AirTripMaker Launches Comprehensive Flight Tickets to India Routes Guide from the USA and Canada to Major Indian Destinations
-
NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development
-
Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
-
Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine
-
SI vs. AI: Super Intelligence Anomaly Outbreaks Trump’d by Clinton Legacy Tech (Veterans First for America)
-
Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)
-
KFSH Expands Virtual Care Pathways to Bring Specialized Follow-Up Closer to Patients
-
BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy
-
Climb Bio Presents Initial PrisMN Phase 2 Data from Budoprutug in pMN at an Oral Session at ASN Kidney Week 2026
-
Teck Provides Update on Highland Valley Copper Operations
-
Online Cricket ID App Publishes Overview of Changing Digital Cricket Information Needs Among Indian Fans
-
UK Financial Ltd Launches MAYA CHAIN and Begins Digital Asset Migration
-
Get Cricket IDs Announces Online Information Resources for Live Cricket Updates, Match Statistics and Mobile Platform Access
-
AI-119 Vulcan Force Solution Targets California's May 2027 Frontier AI Deadline (Veterans First for America)
-
AI-119 Vulcan Force Solution Targets California's May 2027 Frontier AI Deadline (Veterans First for America)
-
Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined
-
Melbourne coach Dominik Kulewski's Weight Loss Lab clients have now lost about 3 tonnes combined
-
Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month
-
Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month
-
2026 National Poppy Campaign launches with a donation “first” … and stunning mural: Don’t forget to Remember
-
Thousands of Ontarians to Attend ‘Together for Publicly Funded Education’ Rallies
-
Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress
-
Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors
-
DEEP Robotics Unveils Five Research Advances in Embodied AI
-
JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value
-
JST Buyback & Burn Upgrade: GasFree Revenue and $20.34M Surplus Injected as JUST's Ecosystem Trio Solidifies JST Token Value
-
NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
-
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
-
Asyad Group to Host Muscat Maritime Resilience Forum to Strengthen Global Trade Networks
-
KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination
-
AirTripMaker Launches Comprehensive Business Class Flight Routes Guide from the USA to 15 Major International Destinations and Regions
-
Celcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
-
Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
-
Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence
-
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
-
Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting
-
Yangguang News Launches Global Youth Short Video Campaign “Me, Tang Poetry, and AI”
-
World Famous Liquor Brands Sustainability Index Report (2026) Released
-
Rooted in the River, Renewed with the Times: Insights from the 2026 Chishui River Forum
-
Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma
-
See It, Try It, Compare It: SIVP Brings CHERY’s “Technology. For Family” to Life
-
Vmake Labs Launches All-in-One Halloween Social Video Toolkit for SMBs
-
Amaggi Luxembourg International S.à r.l. Announces Expiration and Results of Its Cash Tender Offer for Up to U.S.$300 Million Aggregate Principal Amount of Its 5.250% Notes Due 2028
-
Urban Seed Logs Record Harvest in 15th Season, Sets 2027 Focus on Building an Organization That Lasts
